Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507751
2.
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 19(1): 115-126, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29175149
3.
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Ther Adv Med Oncol
; 15: 17588359231178125, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37275963
4.
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
J Clin Oncol
; 37(25): 2206-2216, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157583
5.
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
JAMA Oncol
; 3(6): 767-773, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27737436
6.
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Mol Cancer Ther
; 16(1): 228-238, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27811012
7.
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J Clin Oncol
; 34(5): 443-51, 2016 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26628478